Table 2.
Associations of Tumor Budding and Clinicopathological Features in 109 Gastric Cancer Patients.
| Characteristics | No. of patients (%) | Tumor budding | p (χ2) | |
|---|---|---|---|---|
| Low 59 (54.1) | High 50 (45.9) | |||
| Age group | 0.382(a) | |||
| <30 | 1 (0.9) | 0 | 1 (2.0) | |
| 30-39 | 11 (10.1) | 4(6.8) | 7 (14.0) | |
| 40-49 | 12 (11.0) | 5 (8.5) | 7 (14.0) | |
| 50-59 | 40 (36.7) | 23 (39.0) | 17 (34.0) | |
| ≥60 | 45 (41.3) | 27 (45.8) | 18 (36.0) | |
| Sex | 0.384 | |||
| Male | 68 (62.4) | 39 (66.1) | 29 (58.0) | |
| Female | 41 (37.6) | 20 (33.9) | 21 (42.0) | |
| Lateral | 0.443(a) | |||
| Antrum | 87 (79.8) | 46 (78.0) | 41 (82.0) | |
| Antrum—Lesser curvature | 7 (6.4) | 3 (5.1) | 4 (8.0) | |
| Fundus/Corpus | 5 (4.6) | 4 (6.8) | 1 (2.0) | |
| Corpus—Lesser curvature | 3 (2.8) | 1 (1.7) | 2 (4.0) | |
| Cardia | 3 (2.8) | 1 (1.7) | 2 (4.0) | |
| Pyloric Antrum | 3 (2.8) | 1 (1.7) | 2 (4.0) | |
| Unknown | 1 (0.9) | 1 (1.7) | 0 | |
| Histopathological type | <0.001(a) | |||
| Adenocarcinoma, NOS | 86 (78.9) | 56 (94.9) | 30 (60.0) | |
| Signet ring cell | 16 (14.7) | 0 | 16 (32.0) | |
| Mucinous | 7 (6.4) | 3 (5.1) | 4 (8.0) | |
| Differentiated grade | 0.009(a) | |||
| Well-differentiated | 7 (8.1) | 7 (12.5) | 0 | |
| Moderately-differentiated | 36 (41.9) | 27 (48.2) | 9 (30.0) | |
| Poorly-differentiated | 43 (50.0) | 22 (39.3) | 21 (70.0) | |
| Lauren classification | <0.001 | |||
| Intestinal type | 93 (85.3) | 59 (100.0) | 34 (68.0) | |
| Diffuse type | 16 (14.7) | 0 | 16 (32.0) | |
| LVI | 0.003 | |||
| Absent | 67 (61.5) | 44 (74.6) | 23 (46.0) | |
| Present | 42 (38.5) | 15 (25.4) | 27 (54.0) | |
| Perineural invasion | <0.001 | |||
| Absent | 68 (62.4) | 52 (88.1) | 16 (32.0) | |
| Present | 41 (37.6) | 7 (11.9) | 34 (68.0) | |
| Relapse | <0.001 | |||
| Absent | 78 (71.6) | 56 (94.9) | 22 (44.0) | |
| Present | 31 (28.4) | 3 (5.1) | 28 (56.0) | |
| pT | 0.426(a) | |||
| T1 | 1 (0.9) | 1 (1.7) | 0 | |
| T2 | 18 (16.5) | 13 (22.0) | 5 (10.0) | |
| T3 | 16 (14.7) | 8 (13.6) | 8 (16.0) | |
| T4a | 50 (45.9) | 25 (42.4) | 25 (50.0) | |
| T4b | 24 (22.0) | 12 (20.3) | 12 (24.0) | |
| Lymph node status | <0.001 | |||
| Negative | 40 (36.7) | 28 (47.5) | 12 (24.0) | |
| 1-2 positive node(s) | 42 (38.5) | 20 (33.9) | 22 (44.0) | |
| 3-6 positive nodes | 17 (15.6) | 8 (13.6) | 9 (18.0) | |
| 7-15 positive nodes | 9 (8.3) | 3 (5.1) | 6 (12.0) | |
| > 15 positive nodes | 1 (0.9) | 0 | 1 (2.0) | |
| pTNM stage | 0.124 | |||
| I | 3 (2.8) | 2 (3.4) | 1 (2.0) | |
| IIA | 24 (22.0) | 19 (32.2) | 5 (10.0) | |
| IIB | 24 (22.0) | 12 (20.3) | 12 (24.0) | |
| IIIA | 21 (19.3) | 10 (16.9) | 11 (22.0) | |
| IIIB | 26 (23.9) | 11 (18.6) | 15 (30.0) | |
| IIIC | 11 (10.1) | 5 (8.5) | 6 (12.0) | |
(a): Fisher exact test.